Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center

Casey A. Rimland,[1a] Camille E. Morgan,[1,2a] Griffin J. Bell,[2] Min K. Kim,[3] Tanner Hedrick,[4] Ashley Marx,[4] Brian Bramson,[3] Heidi Swygard,[3] Sonia Napravnik,[2,3] John L. Schmitz,[5] Shannon S. Carson,[6] William A. Fischer,[6] Joseph J. Eron,[3] Cynthia L. Gay,[3] Jonathan B. Parr[3*]
([a]Contributed equally, *Corresponding)

[1] Medical Scientist Training Program, University of North Carolina at Chapel Hill (UNC), Chapel Hill, NC, USA
[2] Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC, USA
[3] Division of Infectious Diseases, UNC School of Medicine, Chapel Hill, NC, USA
[4] Department of Pharmacy, UNC Medical Center, Chapel Hill, NC, USA
[5] Department of Pathology and Laboratory Medicine, UNC School of Medicine, Chapel Hill, NC, USA
[6] Division of Pulmonary Diseases and Critical Care Medicine, UNC School of Medicine, Chapel Hill, NC, USA

Keywords: SARS-CoV-2, tocilizumab, cytokine release syndrome, COVID-19, interleukin 6 (IL-6)

Running title: Tocilizumab outcomes in severe COVID-19

Abstract word count: 48

Manuscript word count: 1368

*** Corresponding author:** Jonathan B. Parr, MD, MPH; 130 Mason Farm Rd, Chapel Hill, NC 27599; jonathan_parr@med.unc.edu

Author contributions:
CAR, CEM extracted data, analyzed data, wrote first draft. GJB analyzed data. MKK extracted data. JBP supervised the study. CAR, CEM, GJB, MKK, TH, AM, BB, SN, JLS, SSC, WAF, JJE, CLG, JBP reviewed and edited the final draft.

Abstract

We describe early outcomes in 11 COVID-19 patients treated with the IL-6 receptor inhibitor tocilizumab. While C-reactive protein decreased, neither clinical improvement nor reduced temperature or oxygen requirements was observed in most patients. Our findings contrast with prior reports and raise questions about tocilizumab use in severe COVID-19.

INTRODUCTION

A hyperinflammatory state is a posited driver of severe COVID-19 [1]. Elevations of IL-6 have been described in acute respiratory distress syndrome and cytokine release syndrome (CRS) [2,3]. Recently, IL-6-driven inflammation in severe COVID-19 was suggested, as increased levels were associated with mortality [4]. IL-6 blockade via tocilizumab, a humanized monoclonal antibody that targets the IL-6 receptor, has been proposed as a treatment for COVID-19 [5].

Peer-reviewed reports of tocilizumab use for COVID-19 are largely limited to retrospective case series from China [6,7] and Italy [8,9], as well as case reports [10–13]. Xu *et al*. reported improved inflammatory markers, oxygen requirements, and fever in 21 patients after tocilizumab treatment [6]. Luo *et al.*'s description of 15 patients included more critically ill patients and more measured results, with 20% mortality [7]. A prospective, open-label study from Italy reported clinical improvement and increased survival after tocilizumab [8], while a second study in Italy found no significant clinical improvement or mortality benefit following tocilizumab [9]. Given the paucity of data on tocilizumab use in COVID-19 in the United States, we evaluated 11 patients treated with tocilizumab for COVID-19. We detail their clinical characteristics before and after treatment and reconsider tocilizumab use in severe COVID-19.

METHODS

We performed a retrospective cohort study of patients with COVID-19 treated with tocilizumab at UNC Medical Center between March 21st and April 25th, 2020. Clinical

67 data was extracted from the medical record. COVID-19 was diagnosed using
68 nasopharyngeal swabs and reverse-transcriptase PCR (RT-PCR). IL-6 testing was
69 conducted at Mayo Clinic Laboratories (Rochester, MN) using an
70 electrochemiluminescence assay. Baseline IL-6 values for two patients were from a multi-
71 cytokine panel (lower-limit of detection [LOD] of 5.0 pg/mL); all others were from a
72 standalone IL-6 assay (LOD 1.8 pg/ml). Disease severity was defined according to the
73 World Health Organization (WHO) COVID-19 clinical status scale with minor modification
74 [14]. Descriptive statistics were calculated using JMP 15 and Wilcoxon signed rank test
75 performed in GraphPad Prism 8. Data was visualized using the *tidyverse* package in R
76 3.6.0. The study was approved by the UNC Institutional Review Board.
77

78 **RESULTS**

79 ***Patient population***

80 Eleven patients with confirmed SARS-CoV-2 infection treated with tocilizumab for COVID-
81 19 were identified and included. Demographic, clinical, and laboratory data are displayed
82 in **Table 1.** Six (55%) patients had an unknown exposure history. Median time from
83 symptom onset to admission was 8 days (IQR=5-11). Most patients were male (82%,
84 n=9); non-white (73%, n=8); non-substance users (82%) with a median age of 59 years
85 old (IQR=48-65). Patients had a median of 2 (IQR=1-6) comorbidities, including
86 hypertension (73%, n=8), type 2 diabetes mellitus (36%, n=4), and lung disease (27%,
87 n=3). Almost all were overweight (36%, n=4) or obese (55%, n=6). Five (46%) took an
88 angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at
89 baseline. Seven (64%) were transferred from outside hospitals, all within one day of initial

presentation. Five (46%) were diagnosed with COVID-19 by SARS-CoV-2 RT-PCR as outpatients prior to presentation.

Baseline laboratory and imaging characteristics

On admission, most patients had significantly elevated inflammatory markers including elevated CRP (100%, n=11/11), fibrinogen (100%, n=9/9), ferritin (80%, n=8/10), LDH (88.9%, n=8/9), and D-dimer (70%, n=7/10). Most patients had normal total white blood cell counts (WBC) (81.82%, n=9/11); two patients had elevated total WBC (18.2%). However, almost all patients presented with low absolute lymphocyte counts (90.9%, n=10/11). Several patients presented with laboratory signs of additional organ damage. Four patients had abnormal troponin I levels (36.4%), five patients had elevated pro-BNP (45.5%), three patients had elevated creatinine (27.3%), and two patients had both elevated AST and ALT (18.2%). Almost all patients had abnormal chest imaging on admission (91%, n=10).

Hospital course

Most patients had severe or critical COVID-19 by modified WHO criteria (55%, n=6) at the time of admission (**Table 1**). All patients required supplemental oxygen on admission, including five (46%) via low-flow nasal cannula (LFNC, ≤ 10L/min), two (18%) via high-flow nasal cannula (HFNC), and four (36%) via mechanical ventilation. During the observation period, eight (73%) were critically ill requiring mechanical ventilation and vasopressors, one (9%) was critically ill requiring mechanical ventilation alone, one (9%) with do-not-intubate status received HFNC only, and one (9%) had mild disease requiring

113 LFNC. Ten of the 11 (91%) received at least one dose of an anti-microbial or
114 immunomodulating treatment during their hospitalization.
115
116 ***Outcomes after tocilizumab***
117 Tocilizumab was administered a median of one day (IQR 1-4) from admission and nine
118 days (IQR 7-14) after symptom onset. Ten patients received a single tocilizumab dose,
119 and one received two doses. Median dosage was 7.9 mg/kg. Two of six patients with
120 available baseline IL-6 levels had low levels, one below the assay's LOD (≤5 pg/mL) and
121 another of 10.4 pg/mL. Four of five with available IL-6 levels after tocilizumab had IL-6
122 levels above the upper limit of quantification. IL-6 increased after tocilizumab in all four
123 patients with matched baseline and post-tocilizumab testing.
124
125 CRP and fibrinogen decreased significantly after tocilizumab (**Figure 1A,** median CRP
126 211.6 vs. 19.7 mg/L [p=0.001] and fibrinogen 767 vs. 420 mg/dL [p=0.002] pre- and 5
127 days post-tocilizumab, respectively). Other laboratory markers did not show clear trends
128 (**Figure 1B**). Temperature did not show obvious improvement (**Figure 1C**), and only
129 three (27%) showed improvement in oxygen requirements (**Figure 1D**). At end of follow-
130 up, patients were observed for a median of 17 days (range=7-34) after initial tocilizumab
131 dose. Three died (27%); five (45%) remained in the intensive care unit (ICU) on
132 mechanical ventilation, receiving vasopressors or hemodialysis; one (9%) was
133 transferred from the ICU to floor status and weaned to room air; and two (18%) were
134 discharged home without oxygen. Seven patients (64%) had minimally elevated liver
135 function tests after tocilizumab administration. Two were diagnosed with ileus and two

136 with bacterial pneumonia after tocilizumab administration; no serious adverse events
137 were observed.
138
139 **DISCUSSION**
140 While tocilizumab was recently described as a promising therapy for severe COVID-19,
141 our findings raise questions about its use in critically ill patients [7]. We report data from
142 patients with COVID-19 treated with tocilizumab at a United States academic center,
143 almost all of whom required ICU care. CRP and fibrinogen improved after tocilizumab
144 administration as previously reported [6–8], but improvement in disease severity or
145 mortality were not observed. These findings, in addition to low baseline IL-6 levels
146 observed in some patients, raise questions about tocilizumab use in patients presenting
147 with severe or critical COVID-19, especially without baseline IL-6 data.
148
149 Important differences exist between our cohort and those from China and Italy [6–9].
150 Three of four studies had few patients requiring mechanical ventilation (n=2/21, n=4/32,
151 and n=5/63 respectively) [6,8,9]; the fourth study did not report specific oxygen
152 requirements but did include more patients reported as critically ill (n=7/15) [7]. Our cohort
153 included higher rates of hypertension (73% versus 40% in Luo *et al*., 37% in Campochiaro
154 *et al.,* and 38% in Sciascia *et al.*); a majority were overweight or obese (91%). We also
155 observed lower baseline IL-6 levels compared to those described in these cohorts,
156 although IL-6 assays were conducted in different laboratories. While Sciascia *et al.*
157 attribute observed survival benefit of tocilizumab treatment to early administration in their
158 Italian cohort [8], we did not observe the same clinical improvement, despite tocilizumab

159 administration within a median of one day of hospitalization. Our findings also
160 demonstrate the challenge of defining CRS in COVID-19, especially in the absence of
161 standardized IL-6 assays and limited data to support IL-6 thresholds for tocilizumab use.
162
163 Our findings contrast with most previous reports and do not provide clear evidence of
164 clinical improvement after tocilizumab treatment in patients with severe COVID-19.
165 Several explanations can be considered. First, our patients were more severely ill than
166 previous cohorts. It is possible tocilizumab was administered too late to offer benefit.
167 Second, our patient cohort was more racially and ethnically diverse and had more
168 comorbidities, notably obesity and hypertension, than those in China and Italy. Third,
169 improvements observed in prior, less severely ill cohorts, might have occurred as part of
170 the normal disease process, with or without tocilizumab.
171
172 In conclusion, tocilizumab reduces inflammatory markers (CRP, fibrinogen), but it is
173 unclear whether its activity leads to equally dramatic effects on clinical outcomes.
174 Randomized controlled trials are essential to determine when, or if, tocilizumab should be
175 used in severe COVID-19.
176

ACKNOWLEDGMENTS

The authors would like to thank the nurses; laboratory staff; and allied health providers involved in the care of these patients. We also thank Carlton Moore and Hannah Little for assistance with initial exploration of data.

Funding

The authors report no designated funding for the project. CAR and CEM receive training support from the University of North Carolina at Chapel Hill Medical Scientist Training Program. CAR additionally receives training support from the National Institutes of Health MD/PhD Partnership Program.

Conflicts of interest

JBP reports research support outside the submitted work from Gilead Sciences and the World Health Organization, and non-financial support from Abbott Laboratories. CLG has received research support outside the submitted work from Viiv Healthcare and Gilead Sciences. SSC reports research support outside of the submitted work from Biomarck Pharmaceuticals.

References

1. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect **2020**; 80:607–613.

2. Aisiku IP, Yamal J-M, Doshi P, et al. Plasma cytokines IL-6, IL-8, and IL-10 are associated with the development of acute respiratory distress syndrome in patients with severe traumatic brain injury. Crit Care Lond Engl **2016**; 20:288.

3. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med **2018**; 24:731–738.

4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet **2020**; 395:1054–1062.

5. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun **2020**; :102452.

6. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci **2020**; :202005615.

7. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol **2020**; :1–5.

8. Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol **2020**; 38:529–532.

9. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med **2020**; 76:43–49.

10. Ferrey AJ, Choi G, Hanna RM, et al. A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. Am J Nephrol **2020**; 51:337–342.

11. Michot J-M, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol **2020**; Available at: https://linkinghub.elsevier.com/retrieve/pii/S0923753420363870. Accessed 5 May 2020.

12. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv **2020**; 4:1307–1310.

228 13. Mihai C, Dobrota R, Schröder M, et al. COVID-19 in a patient with systemic
229 sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis **2020**; 79:668–669.

230 14. World Health Organization. WHO R&D Blueprint novel Coronavirus: COVID-19
231 Therapeutic Trial Synopsis. Geneva, Switzerland: 2020.


A.
C-Reactive Protein
CRP (mg/L)
Time since Tocilizumab (days)
Fibrinogen
Fibrinogen (mg/dL)
Time since Tocilizumab (days)
Median
IQR
Reference Range
B.
White Blood Cell Count
WBC (10^9/L)
Time since Tocilizumab (days)
Absolute Lymphocyte Count
Absolute lymphocytes (10^9/L)
Time since Tocilizumab (days)
Platelet Count
Platelets (10^9/L)
Time since Tocilizumab (days)
Ferritin
Ferritin (ng/mL)
Time since tocilizumab (days)
D-Dimer
D-Dimer (ng/mL)
Time since Tocilizumab (days)
Median
IQR
Reference Range
C.
FiO2 Requirement
Patient 1 (admitted)
Patient 2 (discharged)
Patient 3 (deceased)
Patient 4 (deceased)
Patient 5 (ICU)
Patient 6 (ICU)
Patient 7 (deceased)
Patient 8 (ICU)
Patient 9 (ICU)
Patient 10 (ICU)
Patient 11 (discharged)
ECMO
Fio2 (percent)
Time since Tocilizumab (hours)
D.
Temperature
Temperature (celsius)
Time since Tocilizumab (hours)

233 **Figure 1. Laboratory and clinical outcomes of patients treated with tocilizumab.** (**A-**
234 **B**) Laboratory trends following tocilizumab. Medians (blue lines), interquartile ranges
235 (IQR, blue shading), and reference ranges (dashed red lines). (**C-D**) Oxygen
236 requirements and temperature trends, displayed using locally estimated scatterplot
237 smoothing (orange lines). Patient #6 was treated with two doses of tocilizumab; time 0
238 refers to the time of initial administration.

239 **Table 1. Patients with COVID19 treated with tocilizumab demographics and**

240 **clinical characteristics (n=11).**

Demographics and Clinical Characteristics	Median (IQR) / Percentage (n)
Age / Male sex	59 (48-65) / 82% (9)
Race	
Hispanic/Latino	46% (5)
Caucasian	27% (3)
African American	27% (3)
Tobacco / ethanol / substance use	9% (1) / 9% (1) / 9% (1)
BMI	31 (29-36)
Normal (18.5-25)	9% (1)
Overweight (25-30)	36% (4)
Obese (>30)	55% (6)
Comorbidities	
Hypertension	73% (8)
Type 2 diabetes mellitus	36% (4)
Lung disease	27% (3)
Cardiovascular disease	18% (2)
Liver disease	9% (1)
Renal disease	9% (1)
HIV	9% (1)
Active cancer	9% (1)
Solid organ transplant	9% (1)
ACE/ARB treatment	46% (5)
COVID-19 Clinical and Treatment Characteristics	
Time from symptom onset to admission	8 (5-11)
Abnormal CXR/CT on admission	91% (10)
Prone positioning while intubated	78% (7/9)
Dosage of tocilizumab (mg/kg)	7.9 (5.8-8.1)*

Other treatments		
Azithromycin	64% (7)	
Hydroxychloroquine	36% (4)	
Ritonavir/Lopinavir	27% (3)	
Steroids	27% (3)	
Admission labs[#]	*Median (IQR)*	*Percentage abnormal (n)*
CRP (mg/L)	197.3 (146.8-324.9)	100% (11/11 elevated)
Fibrinogen (mg/dL)	662.0 (566-928.5)	100% (9/9 elevated)
Ferritin (ng/mL)	589.5 (389.8-1705)	80% (8/10 elevated)
LDH (U/L)	1203 (943-2122)	89% (8/9 elevated)
D-Dimer (ng/mL)	343.5 (199.5-1,203)	70% (7/10 elevated)
WBC ($x10^9$/L)	8.5 (5.1-9.9)	18% (2/11 elevated)
Absolute lymphocyte count ($x10^9$/L)	0.8 (0.6-1)	91% (10/11 reduced)
Platelet count ($x10^9$/L)	230 (162-382)	18% (2/11 reduced)
Troponin I (ng/mL)	<0.034 (<0.034-0.172)	36% (4/11 elevated)
Creatinine (mg/dL)	0.92 (0.7-2.53)	27% (3/11 elevated)
Pro-BNP (pg/mL)	69.7 (34.3-6,870)	46% (5/11 elevated)
AST (U/L)	51 (44-72)	46% (5/11 elevated)
ALT (U/L)	35 (30-60)	27% (3/11 elevated)

Clinical and Laboratory Outcomes

Disease severity	*Admission*	*Highest Severity*	*Outcome*
8 (Deceased)	---	---	27% (3)
7 (Critical, Ventilator + Organ Support)	36% (4)	73% (8)	46% (5)
6 (Critical, Ventilator)	0% (0)	9% (1)	0% (0)
5 (Severe, HFNC/NIPPV)	18% (2)[***]	9% (1)[***]	0% (0)
4 (Mild, LFNC)	36% (4)	9% (1)	0% (0)
3 (Mild, room air)	9% (1)	0% (0)	9% (1)
1-2 (Ambulatory – Discharged)	---	---	18% (2)
Other invasive therapies			
Hemodialysis/CRRT	27% (3)		
ECMO	9% (1)		

Length of stay (days)**	18 (15-25)		
Length (days) on mechanical ventilation**	17 (12-29)		
Laboratory measures#	*Pre-Tocilizumab*	*Post-Tocilizumab*	*p-value*
CRP (mg/L)	211.6 (176.9-313.8)	19.7 (13.6-29)	0.001
Fibrinogen (mg/dL)	767 (625-862)	420 (386.3-473.5)	0.002
IL-6 (pg/mL)	30.65 (9.1–88.8)	>400 (249.4 - >400)	0.13##

241

242 * n=12 doses; one patient received tocilizumab twice.

243 ** As of date of death, date of discharge, or end date of observation period.

244 *** One patient was do not intubate status on admission, receiving only HFNC/NIPPV. Patient subsequently died.

245 # Not all patients had all laboratory values available, data representative of patients with data available.

246 ## Only four patients had matched pre- and post-Tocilizumab IL-6 levels.

247

248 Abbreviations: OSH, outside hospital; BMI, body mass index; CXR, chest x-ray; CT, computed tomography; HIV,
249 human immunodeficiency virus; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker;
250 CRP, c-reactive protein; LDH, lactate dehydrogenase; WBC, white blood cell count; BNP, b-type natriuretic peptide;
251 AST, aspartate aminotransferase; ALT, alanine aminotransferase; HFNC, high-flow nasal cannula; NIPPV, non-
252 invasive positive pressure ventilation; LFNC, low-flow nasal cannula; CRRT, continuous renal replacement therapy;
253 ECMO, extracorporeal membrane oxygenation; IL-6, interleukin-6.